Tivantinib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tivantinib" in English language version.

refsWebsite

Global rank English rank

2web.archive.org

1^st place

1^st place

79^th place

65^th place

2^nd place

2^nd place

4^th place

4^th place

1genengnews.com

low place

6,625^th place

low place

low place

arqule.com

"Tivantinib (ARQ 197)". ArQule. Archived from the original on 14 March 2017.

doi.org

Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, et al. (May 2013). "Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET". Clinical Cancer Research. 19 (9): 2381–92. doi:10.1158/1078-0432.CCR-12-3459. PMID 23532890.

genengnews.com

"ArQule, Daiichi Sankyo Say Cancer Candidate Tivantinib Fails Phase III Trial". Genetic Engineering & Biotechnology News. February 2017.

nih.gov

pubmed.ncbi.nlm.nih.gov

Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, et al. (May 2013). "Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET". Clinical Cancer Research. 19 (9): 2381–92. doi:10.1158/1078-0432.CCR-12-3459. PMID 23532890.

web.archive.org

"ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko Kirin in Japan". The Wall Street Journal. 4 February 2014. Archived from the original on 22 February 2014.
"Tivantinib (ARQ 197)". ArQule. Archived from the original on 14 March 2017.

wsj.com

online.wsj.com

"ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko Kirin in Japan". The Wall Street Journal. 4 February 2014. Archived from the original on 22 February 2014.